Estimating Patient Time Costs Associated With Colorectal Cancer Care

Background:Nonmedical costs of care, such as patient time associated with travel to, waiting for, and seeking medical care, are rarely measured systematically with population-based data. Objectives:The purpose of this study was to estimate patient time costs associated with colorectal cancer care. Methods:We identified categories of key medical services for colorectal cancer care and then estimated patient time associated with each service category using data from national surveys. To estimate average service frequencies for each service category, we used a nested case control design and SEER-Medicare data. Estimates were calculated by phase of care for cases and controls, using data from 1995 to 1998. Average service frequencies were then combined with estimates of patient time for each category of service, and the value of patient time assigned. Net patient time costs were calculated for each service category, summarized by phase of care, and compared with previously reported net direct costs of colorectal cancer care. Results:Net patient time costs for the 3 phases of colorectal cancer care averaged $4592 (95% confidence interval [CI] $4427–4757) over the 12 months of the initial phase, $2788 (95% CI $2614–2963) over the 12 months of the terminal phase, and $25 (95% CI: $23–26) per month in the continuing phase of care. Hospitalizations accounted for more than two thirds of these estimates. Patient time costs were 19.3% of direct medical costs in the initial phase, 15.8% in the continuing phase, and 36.8% in the terminal phase of care. Conclusions:Patient time costs are an important component of the costs of colorectal cancer care. Application of this method to other tumor sites and inclusion of other components of the costs of medical care will be important in delineating the economic burden of cancer in the United States.

[1]  D. Whynes,et al.  Estimating time and travel costs incurred in clinic based screening: flexible sigmoidoscopy screening for colorectal cancer , 1999, Journal of medical screening.

[2]  J Lipscomb,et al.  The burden of illness of cancer: economic cost and quality of life. , 2001, Annual review of public health.

[3]  K. Kuntz,et al.  Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Sloan Access to Medical Care and the Local Supply of Physicians , 1977, Medical care.

[5]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[6]  Anne C. Haddix,et al.  Prevention effectiveness : a guide to decision analysis and economic evaluation , 1996 .

[7]  H. Stambler,et al.  The Area Resource File--a brief look. , 1988, Public health reports.

[8]  M. Choti,et al.  NCCN Practice Guidelines for Colorectal Cancer. , 2000, Oncology.

[9]  Martin L. Brown,et al.  Economic Impact of Cancer in the United States , 2006 .

[10]  A. Feinstein Para-analysis, faute de mieux, and the perils of riding on a data barge. , 1989, Journal of clinical epidemiology.

[11]  N Urban,et al.  Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. , 1995, Journal of the National Cancer Institute.

[12]  W. Barlow,et al.  Survival and Treatment for Colorectal Cancer Medicare Patients in Two Group/Staff Health Maintenance Organizations and the Fee-for-Service Setting , 1999, Medical care research and review : MCRR.

[13]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[14]  M. Sculpher,et al.  Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy , 2000, PharmacoEconomics.

[15]  S. Vernon,et al.  Quality of care for colorectal cancer in a fee‐for‐service and health maintenance organization practice , 1992, Cancer.

[16]  M. Fay,et al.  Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. F. Athas,et al.  Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. , 2000, Journal of the National Cancer Institute.

[18]  W. Nordhaus,et al.  The Health of Nations: The Contribution of Improved Health to Living Standards , 2002 .

[19]  D. Makuc,et al.  Travel for Ambulatory Medical Care , 1983, Medical care.

[20]  W. Lawrence,et al.  Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  P. Livingston,et al.  Personal costs incurred by women attending a mammographic screening programme , 1991, The Medical journal of Australia.

[22]  R. Winn,et al.  Transportation as a barrier to cancer treatment. , 1997, Cancer practice.

[23]  A S Detsky,et al.  Screening for breast cancer: time, travel, and out-of-pocket expenses. , 1999, Journal of the National Cancer Institute.

[24]  M. Brown,et al.  Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. , 1994, American journal of public health.

[25]  B. Hankey,et al.  Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. , 1995, Cancer.

[26]  W. Lawrence,et al.  Benefits and costs of using HPV testing to screen for cervical cancer. , 2002, JAMA.

[27]  S. Goldie,et al.  TIME COSTS ASSOCIATED WITH CERVICAL CANCER SCREENING , 2001, International Journal of Technology Assessment in Health Care.

[28]  Stambler Hv The Area Resource File--a brief look. , 1988 .

[29]  Rural Economy Division.,et al.  Rural-Urban Continuum Codes for Metro and Nonmetro Counties, 1993 , 1990 .

[30]  C. Roelofs Prevention effectiveness: A guide to decision analysis and economic evaluation , 1997 .

[31]  L. Kessler,et al.  Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis , 1995, Medical care.

[32]  R D Etzioni,et al.  Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. , 1999, Medical care.

[33]  J. Fraumeni,et al.  Cancer epidemiology and prevention. , 2006 .

[34]  P. Cohen,et al.  Regulation of the Epithelial Ca2+ Channel TRPV5 by the NHE Regulating Factor NHERF2 and the Serum and Glucocorticoid Inducible Kinase Isoforms SGK1 and SGK3 Expressed in Xenopus oocytes , 2004, Cellular Physiology and Biochemistry.

[35]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[36]  J. Berlin,et al.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Gregory S. Cooper,et al.  Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.